文献速递心力衰竭与心肌病

环核苷酸磷酸二酯酶10A在病理性心脏重构与功能障碍中的新作用

A Novel Role of Cyclic Nucleotide Phosphodiesterase 10A in Pathological Cardiac Remodeling and Dysfunction.
PubMed 文献 · Circulation · 2019-12-05

该研究在分离的小鼠心肌细胞和成纤维细胞及临床前小鼠模型中,探讨了PDE10A在心脏重构和心衰中的调控与功能。PDE10A在人和小鼠衰竭心脏中显著上调,抑制或敲除PDE10A可减轻病理性心肌肥厚、纤维化和功能障碍,并逆转已建立的心脏重构。

要点

  • PDE10A在衰竭心脏中显著上调,正常和运动心脏中表达较低。
  • 抑制PDE10A可减轻Ang II、苯肾上腺素和异丙肾上腺素诱导的病理性心肌肥厚,但不影响IGF-1诱导的生理性肥厚。
  • TP-10可逆转已建立的心脏肥厚和功能障碍,提示PDE10A抑制是潜在治疗策略。

核心结论

  • PDE10A在病理性心脏重构和心衰发展中起重要作用,抑制PDE10A可能成为预防和治疗心脏重构相关疾病的新策略。

研究设计与样本

  • 研究使用分离的成年小鼠心肌细胞和成纤维细胞,以及肥厚和心衰的临床前小鼠模型。
  • 采用PDE10A选择性抑制剂TP-10和全局PDE10A敲除小鼠。

主要发现

  • PDE10A在正常和运动心脏组织中表达相对较低,但在小鼠和人衰竭心脏中显著上调。
  • PDE10A缺陷或用TP-10抑制PDE10A,可减轻血管紧张素II、苯肾上腺素和异丙肾上腺素诱导的心肌细胞病理性肥厚,但不影响IGF-1诱导的生理性肥厚。
  • TP-10减少TGF-β刺激的心脏成纤维细胞活化、增殖、迁移和细胞外基质合成。
  • TP-10提高心肌细胞和心脏成纤维细胞中cAMP和cGMP水平,与PDE10A作为cAMP/cGMP双特异性PDE一致。
  • 全局PDE10A缺陷显著减轻横向主动脉缩窄或血管紧张素II输注诱导的心肌肥厚、心脏纤维化和功能障碍。

临床怎么用

  • PDE10A抑制可能作为预防和治疗心脏重构相关疾病(如心衰)的新型治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Heart failure is a leading cause of death worldwide. Cyclic nucleotide phosphodiesterases (PDEs), through degradation of cyclic nucleotides, play critical roles in cardiovascular biology and disease. Our preliminary screening studies have revealed PDE10A upregulation in the diseased heart. However, the roles of PDE10A in cardiovascular biology and disease are largely uncharacterized. The current study is aimed to investigate the regulation and function of PDE10A in cardiac cells and in the progression of cardiac remodeling and dysfunction. METHODS: We used isolated adult mouse cardiac myocytes and fibroblasts, as well as preclinical mouse models of hypertrophy and heart failure. The PDE10A selective inhibitor TP-10, and global PDE10A knock out mice were used. RESULTS: We found that PDE10A expression remains relatively low in normal and exercised heart tissues. However, PDE10A is significantly upregulated in mouse and human failing hearts. In vitro, PDE10A deficiency or inhibiting PDE10A with selective inhibitor TP-10, attenuated cardiac myocyte pathological hypertrophy induced by Angiotensin II, phenylephrine, and isoproterenol, but did not affect cardiac myocyte physiological hypertrophy induced by IGF-1 (insulin-like growth factor 1). TP-10 also reduced TGF-β (transforming growth factor-β)-stimulated cardiac fibroblast activation, proliferation, migration and extracellular matrix synthesis. TP-10 treatment elevated both cAMP and cGMP levels in cardiac myocytes and cardiac fibroblasts, consistent with PDE10A as a cAMP/cGMP dual-specific PDE. In vivo, global PDE10A deficiency significantly attenuated myocardial hypertrophy, cardiac fibrosis, and dysfunction induced by chronic pressure overload via transverse aorta constriction or chronic neurohormonal stimulation via Angiotensin II infusion. Importantly, we demonstrated that the pharmacological effect of TP-10 is specifically through PDE10A inhibition. In addition, TP-10 is able to reverse pre-established cardiac hypertrophy and dysfunction. RNA-Sequencing and bioinformatics analysis further identified a PDE10A-regualted transcriptome involved in cardiac hypertrophy, fibrosis, and cardiomyopathy. CONCLUSIONS: Taken together, our study elucidates a novel role for PDE10A in the regulation of pathological cardiac remodeling and development of heart failure. Given that PDE10A has been proven to be a safe drug target, PDE10A inhibition may represent a novel therapeutic strategy for preventing and treating cardiac diseases associated with cardiac remodeling.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Chen S, Zhang Y, Lighthouse JK, et al. A Novel Role of Cyclic Nucleotide Phosphodiesterase 10A in Pathological Cardiac Remodeling and Dysfunction. Circulation. 2019. PMID: 31801360. doi:10.1161/CIRCULATIONAHA.119.042178

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。